Abstract Background Bladder cancer (BCa) is the ninth frequent and 13th leading cause of
cancer related deaths in the world which is mainly observed among men. There is a …

Bladder cancer is the 10th most common cancer worldwide. It is a heterogeneous disease,
comprising several tumor subtypes with differences in histology, genomic aberrations …

The clinical management of bladder cancer (BC) has become an increasing challenge due
to high incidence rate of BC, malignant behavior of cancer cells and drug resistance. The …

Major fraction of the human genome is transcribed in to the RNA but is not translated in to
any specific functional protein. These transcribed but not translated RNA molecules are …

The mortality and morbidity that characterize bladder cancer compel this malignancy into the
category of hot topics in terms of biomolecular research. Therefore, a better knowledge of …

Bladder cancer (BC) is the most common malignant tumor in the urinary system, and its early
diagnosis is conducive to improving clinical prognosis and prolonging overall survival time …

Background Numerous studies have demonstrated the involvement of long non-coding
RNAs (lncRNAs) in the tumorigenesis of bladder cancer (BC). The aim of this study was to …

Bladder cancer (BCa) is associated with significant morbidity, with development linked to
environmental, lifestyle, and genetic causes. Recurrence presents a significant issue and is …

Bladder cancer (BC) is a common and serious type of cancer that ranks among the top ten
most prevalent malignancies worldwide. Due to the high occurrence rate of BC, the …

Approximately 20% of patients with bladder cancer are diagnosed with muscle‐invasive
disease (MIBC). The treatment involves radical cystectomy, but almost 50% of patients with …